4-1BB/CD137 Rabbit Monoclonal Antibody (Clone RM471)

4-1BB, also known as CD137, is a type I transmembrane glycoprotein and member of the TNF receptor superfamily with roles in T cell-mediated immunity.¹ It is composed of an N-terminal extracellular domain comprising a signaling sequence and four cysteine-rich pseudo repeats (CRDs), a helical transmembrane domain, and a cytoplasmic signaling domain.² 4-1BB is transiently expressed on antigen-primed activated T cells, activated natural killer (NK) cells, and mature dendritic cells. Binding of homotrimeric 4-1BB ligand on antigen-primed T cells induces NF-κB and MAPK signaling through TNF receptor-associated factors (TRAFs) and, when the T cell is co-stimulated by other factors, induces PI3K signaling.^3,1 This bidirectional signaling event promotes clonal expansion, differentiation, and survival of T cells, as well as polarizes T helper cells.⁴ Knockout of Tnfrsf9, the gene encoding 4-1BB, reduces pancreatic islet accumulation of β-cell-autoreactive CD8⁺ T cells in a mouse model of type 1 diabetes mellitus. Administration of an anti-4-1BB antibody prolongs survival and reverses renal damage, production of autoantibodies, and immune complex deposition in lupus-prone NZB X NZW F1 mice. Cayman’s 4-1BB/CD137 Rabbit Monoclonal Antibody (Clone RM471) can be used for flow cytometry (FC), immunohistochemistry (IHC), and Western blot (WB) applications.

WARNING This product is not for human or veterinary use.

1. So, T., and Ishii, N. The TNF–TNFR family of co-signal molecules. Co-signal molecules in T cell activation 53-84 (2019).

2. Chin, S.M., Kimberlin, C.R., Roe-Zurz, Z., et al. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab. Nat. Commun. 9(1), 4679 (2018).

3. Barsoumian, H.B., Batra, L., Shrestha, P., et al. A novel form of 4-1BBL prevents cancer development via nonspecific activation of CD4⁺ T and natural killer cells. Cancer Res. 79(4), 783-794 (2019).

4. Wong, H.Y., and Schwarz, H. CD137 / CD137 ligand signalling regulates the immune balance: A potential target for novel immunotherapy of autoimmune diseases. J. Autoimmun. 112, 102499 (2020).